About Congenica
Congenica is a Healthcare company based in Cambridge (United Kingdom) founded in 2013 by Nick Lench, Richard Durbin, and Matthew Hurles, and was acquired by SeqOne in September 2025. Clinical genome analytics platform is offered for genetic disease treatment. Congenica has raised $81.91 million across 11 funding rounds from investors including Tencent, BGI and Downing. The company has 79 employees. Its chief executive, as recorded, is Rob Denison. Congenica offers products and services including Congenica Platform and Clinical Interpretation Services. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is CONGENICA LTD.
Company details
Congenica was founded in 2013 and is based in Cambridge, United Kingdom. The company operates in the genomics and healthcare sector, providing a platform for clinical genome analytics. This platform enables detection of complex mutations, filtering of clinically relevant variants, and deep phenotyping. Client data is organized with a focus on outcomes, stored securely, and integrated through intuitive tools for interrogation and sharing.
- Headquarters Cambridge, United Kingdom
- Employees 79
- Founders Nick Lench, Richard Durbin, Matthew Hurles
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website congenica.com
- Social LinkedIn X Facebook
- Acquired by SeqOne (Sep 2025)
- Legal Name Congenica Ltd
- Date of Incorporation 30 Oct, 2012
- Jurisdiction CAMBRIDGE, ENGLAND
- Annual Revenue$6.06 M (USD)15as on Dec 31, 2023
- Net Profit-$13.94 M (USD)17as on Dec 31, 2023
- EBITDA-$14.89 M (USD)18as on Dec 31, 2023
- Total Equity Funding$81.91M (USD)
in 11 rounds
- Latest Funding Round$2.81M (USD), Grant
Jun 2021
- InvestorsTencent
& 18 more
- Employee Count79
- Acquired bySeqOne
(Sep 2025)
Products & Services of Congenica
Congenica offers a comprehensive portfolio of products and services, including Congenica Platform and Clinical Interpretation Services.
Software for automated genomic data analysis and interpretation
Services for interpreting genetic data in clinical settings
Funding Insights of Congenica
Congenica has successfully raised a total of $81.91M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $2.81 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $81.91M
- Total Rounds 11
- Last Round Grant — $2.81M
- First Round $337,720
(May 2014)
- Investors Count 18
Latest 10 of 11 funding rounds of Congenica with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $2.81M | Grant | – | – | |
| Nov 2020 | $50M | Series C | – | Tencent, Legal & General | |
| Apr 2019 | $17.13M | Series B | – | Parkwalk | |
| Apr 2017 | Series B | – | – | ||
| Feb 2017 | $10M | Series B | – | – | |
| Jan 2017 | $34,582 | Grant | – | – | |
| Sep 2015 | $455,780 | Grant | – | – | |
| May 2015 | $3.09M | Grant | – | – | |
| Apr 2015 | $3.22M | Series A | – | – | |
| Dec 2014 | $1.56M | Seed | – | – |
19 investors in total: 19 institutional.
Investors in Congenica
Congenica has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Tencent, BGI and Downing.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investment firm | xeraya.com | Kuala Lumpur, Malaysia | ||
Health and technology startups are invested in by Puhua Capital. | puhuacapital.com | Hangzhou, China | ||
Startups are targeted for investments by this venture capital firm. | ido.om | Muscat, Oman | ||
| cicplc.co.uk | ||||
Tech companies are invested in by Parkwalk venture capital firm. | parkwalkadvisors.com | London, United Kingdom | ||
Early-stage companies are invested in by QVentures venture capital fund. | qventures.co | London, United Kingdom | ||
Inheritance tax relief, funds, and bonds are provided across sectors. | 1986 | downing.co.uk | London, United Kingdom | |
Impact-led venture capital is invested in university spin-outs and start-ups. | futureplanetcapital.com | London, United Kingdom | ||
Early-stage deep technology investments are made by Amadeus Capital. | amadeuscapital.com | London, United Kingdom | ||
Research and innovation funding is managed for UK advancement. | 2018 | ukri.org | Swindon, United Kingdom |
Investor details for Congenica
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Congenica
19 people are tracked at Congenica (10 in leadership, 5 in board & advisors, 4 in team); the tracked headcount is 79.
| Name | Role | Group |
|---|---|---|
Nick Lench | Co-Founder | Leadership |
Richard Durbin | Co-Founder | Leadership |
Matthew Hurles | Co-Founder | Leadership |
Michael Leith Anstey | Board Member | Leadership |
Rob Denison | CEO | Leadership |
Robert Denison | CEO | Leadership |
Alistair Johnson | Chief Commercial Officer (cco) | Leadership |
Helen Savage, DipRCPath | Acting Chief Scientific Officer And Director Of Clinical Science | Leadership |
Jayesh Pankhania | CFO | Leadership |
Heike Fiegler | Director Of Marketing | Leadership |
David Shi | Director | Board & advisors |
Anne O’Donnell Luria | Scientific Advisor | Board & advisors |
Ridhi Gupta | Director | Board & advisors |
Andy Richards | Executive Chairman | Board & advisors |
Heiner Dreismann | Director | Board & advisors |
Victoria Hewitt | Clinical Interpretation Service Lead & Clinical Scientist Oncology Lead | Team |
Simon Baker | Technical Author | Team |
Ami Francis | Executive PA/ Office Coordinator | Team |
Abbie Southby | HR & Finance Generalist | Team |
Complete people profiles for Congenica
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Congenica
4 dated milestones of Congenica across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Congenica is founded.
- Funding First funding round of $338K.
- Funding Latest funding round, Grant, of $2.8M.
- Exit Acquired by SeqOne.
Web traffic of Congenica
The website of Congenica (congenica.com) receives about 3.6K visits a month and ranks #4,325,170 among all websites worldwide, #5,303 in Biotechnology and Pharmaceuticals.
- Monthly visits3.6K
▲ 4.1% vs previous month
- Unique visitors1.5K
per month
- Global rank#4,325,170
among all websites
- Category rank#5,303
Health · Biotechnology and Pharmaceuticals
- Bounce rate64%
- Pages per visit2.5
- Average visit1 min 07 sec
- DevicesDesktop 23% · Mobile 77%
Websites whose visitors overlap most with Congenica. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| phgfoundation.org | 100% | 15.8K | #1,675,344 | View details | |
| genomeweb.com | 83% | 116.4K | #371,609 | View details |
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as Congenica (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Congenica
Complete news archive for Congenica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Congenica
Congenica was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Congenica is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Rob Denison is the CEO of Congenica, as recorded in our data.
Congenica is a funded company, having raised a total of $81.91M across 11 funding rounds to date. The company's 1st funding round was a Seed of $1.56M, raised on May 2014.
Congenica has 79 employees.
Annual revenue of Congenica is $6.06M as on Dec 31, 2023.
Congenica was founded in 2013 and is based in Cambridge, United Kingdom. The company operates in the genomics and healthcare sector, providing a platform for clinical genome analytics. This platform enables detection of complex mutations, filtering of clinically relevant variants, and deep phenotyping. Client data is organized with a focus on outcomes, stored securely, and integrated through intuitive tools for interrogation and sharing.
Congenica offers Congenica Platform and Clinical Interpretation Services.
Congenica has 19 investors. Key investors include Tencent, BGI, Downing, SeqOne, and Legal & General.
Congenica operates through Congenica Ltd.
Yes. Congenica was acquired by SeqOne in September 2025.